Bill
SB 150
SB 150 modifies Connecticut's ADHD prescription drug regulations, affecting patient access, healthcare providers, and substance abuse prevention policies.
SB 150 proposes modifications to Connecticut's regulations governing prescription drugs used to treat Attention-Deficit/Hyperactivity Disorder (ADHD). The bill has been referred to the Joint Committee on General Law but the specific provisions have not yet been publicly detailed in available legislative records. Without access to the full text, the precise nature of the proposed changes—whether involving prescription limits, prior authorization requirements, insurance coverage, or other regulatory measures—cannot be definitively stated.
ADHD medications are among the most commonly prescribed drugs for both children and adults, affecting healthcare access for hundreds of thousands of Connecticut residents. Regulatory changes to ADHD prescriptions can impact patient access, insurance costs, pharmacy practices, and the balance between controlling substance abuse potential and ensuring appropriate treatment availability. Any modifications to how these medications are prescribed or distributed carry significant implications for patients, healthcare providers, and public health policy.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
